Diffuse Large B-Cell Lymphoma News

News

Tisagenlecleucel Associated With Improved Response Rates, Reduced Risk of Death vs Historical Treatments for DLBCL

06/14/2022

Third-line or later treatment with tisagenlecleucel is associated with significantly higher response rates and significantly lower risk of death compared with historical control treatments for patients with relapsed/refractory DLBCL.

Third-line or later treatment...

06/14/2022

Oncology

News

Axicabtagene Ciloleucel Significantly Improves Outcomes Over Standard Care as Second-Line Therapy for Large B-cell Lymphoma

05/13/2022

John Otrompke , BA, JD;

Findings from the ZUMA-7 trial suggest axicabtagene ciloleucel is an effective alternative option for the second-line treatment of relapsed or refractory large B-cell lymphoma.

Findings from the ZUMA-7 trial...

05/13/2022

Oncology

News

Second-Line Tisagenlecleucel vs Standard Salvage Therapy for Aggressive B-cell Lymphoma

05/13/2022

John Otrompke , BA, JD;

Second-line treatment with tisagenlecleucel was not superior to standard salvage therapy for patients with aggressive B-cell lymphoma, according to findings from the phase 3 BELINDA trial.

Second-line treatment with...

05/13/2022

Oncology

News

Polatuzumab Vedotin Improves PFS in Previously Untreated DLBCL

05/03/2022

John Otrompke , BA, JD;

A modified regimen of R-CHOP in which vincristine is replaced with polatuzumab vedotin yielded lower risk of disease progression, relapse, or death among patients with previously untreated intermediate-risk or high-risk DLBCL.

A modified regimen of R-CHOP in...

05/03/2022

Oncology

News

Post-transplant Pembrolizumab May Delay Immune Reconstitution for Patients With DLBCL

04/07/2022

John Otrompke , BA, JD;

Patients with DLBCL who received pembrolizumab as maintenance therapy following an autoHSCT experienced a delay of at least 18 months in the reconstitution of their CD19-positive cells, according to a flow cytometry study.

Patients with DLBCL who received...

04/07/2022

Oncology

News

FDA Approves Axicabtagene Ciloleucel for Relapsed or Refractory LBCL

04/04/2022

Emily Bader ;

The FDA approved axicabtagene ciloleucel for patients with LBCL that are refractory to or have relapsed within 12 months of first-line chemoimmunotherapy.

The FDA approved axicabtagene...

04/04/2022

Oncology

Conference Insider

Dr Leonard Highlights Crucial New Data, Practice Changing Therapies in DLBCL

03/23/2022

Alex Stoia ;

John Leonard, MD, presents novel data with CAR-T therapies in upfront, second line DLBCL during the virtual Great Debates & Updates in Hematologic Malignancies.

John Leonard, MD, presents novel...

03/23/2022

Oncology

News

CAR T-Cell Therapy With TanCAR7 Demonstrates Efficacy in DLBCL

03/21/2022

John Otrompke , BA, JD;

Some 70% of R/R NHL patients treated with tandem CD19/CD20 CAR T-cell therapy experienced a CR, findings from a single-arm phase 1/2 trial suggest.

Some 70% of R/R NHL patients...

03/21/2022

Oncology

News

Axicabtagene Ciloleucel Demonstrates Higher ORR in Japanese Patients With Relapsed or Refractory DLBCL

03/08/2022

John Otrompke , BA, JD;

In a bridging study, the CAR T-cell therapy axicabtagene ciloleucel demonstrated efficacy in Japanese patients with R/R DLBCL. The ORR was 86.7%, which was even higher than it was in the pivotal ZUMA-1 study, which did not include any...

In a bridging study, the CAR...

03/08/2022

Oncology

News

Umbralisib Associated With a Better Safety Profile Than Other PI3K Inhibitors

03/01/2022

The use of single-agent umbralisib in adults with R/R NHL, including DLBCL, is associated with a favorable tolerability profile, including low rates of serious immune-mediated toxicities.

The use of single-agent...

03/01/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology